Adrian D Cook
Overview
Explore the profile of Adrian D Cook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parker C, Clarke N, Cook A, Petersen P, Catton C, Cross W, et al.
Eur Urol
. 2024 Aug;
86(5):422-430.
PMID: 39217077
Background And Objective: The use and duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) have been uncertain. RADICALS-HD compared adding no ("None"), 6-months ("Short"), or 24-mo ("Long") ADT...
2.
Parker C, Clarke N, Cook A, Kynaston H, Catton C, Cross W, et al.
Lancet
. 2024 May;
403(10442):2405-2415.
PMID: 38763154
Background: Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of...
3.
Parker C, Kynaston H, Cook A, Clarke N, Catton C, Cross W, et al.
Lancet
. 2024 May;
403(10442):2416-2425.
PMID: 38763153
Background: Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with...
4.
Petersen P, Cook A, Sydes M, Clarke N, Cross W, Kynaston H, et al.
Int J Radiat Oncol Biol Phys
. 2023 May;
117(3):624-629.
PMID: 37150260
Purpose: Emerging data indicate comparable disease control and toxicity of normal postoperative fractionation and moderate hypofractionation radiation therapy (RT) in prostate cancer. In RADICALS-RT, patients were planned for treatment with...
5.
Clamp A, James E, McNeish I, Dean A, Kim J, ODonnell D, et al.
Lancet Oncol
. 2022 Jun;
23(7):919-930.
PMID: 35690073
Background: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with...
6.
Rush H, Murphy L, Morgans A, Clarke N, Cook A, Attard G, et al.
J Clin Oncol
. 2021 Nov;
40(8):825-836.
PMID: 34757812
Purpose: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate...
7.
Morgan R, McNeish I, Cook A, James E, Lord R, Dark G, et al.
Lancet Oncol
. 2020 Dec;
22(2):277-288.
PMID: 33357510
Background: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated...
8.
Parker C, Clarke N, Cook A, Kynaston H, Petersen P, Catton C, et al.
Lancet
. 2020 Oct;
396(10260):1413-1421.
PMID: 33002429
Background: The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with...
9.
James E, Dunn D, Cook A, Clamp A, Sydes M
Trials
. 2020 Sep;
21(1):802.
PMID: 32943106
Background: Safety data is required to be collected in all clinical trials and can be separated into two types of data, adverse events and serious adverse events. Often, these types...
10.
James E, McNeish I, Cook A, Kaplan R, Clamp A
Lancet
. 2020 Sep;
396(10253):757.
PMID: 32919511
No abstract available.